Significance of cytogenetic abnormalities in patients with polycythemia vera.

Abstract

We analyzed 133 patients with polycythemia vera (PV) who were followed at our institution (median 7.5 years) and had adequate cytogenetics information. The 5-, 10- and 15-year survival rates were 93%, 79% and 64%, respectively, with a median projected overall survival of 24 years. Nineteen patients (14%) had abnormal cytogenetics at any time during the disease course (no survival difference). Sixteen patients (12%) underwent disease transformation during follow-up, after a median of 8.5 years, to myelofibrosis (n = 11), acute myeloid leukemia (n = 4) or myelodysplastic syndrome (n = 1); eight had cytogenetic abnormalities. Among 133 patients, 39 were newly diagnosed: 33 with normal and six with abnormal cytogenetics (no survival difference); nine underwent disease transformation (six with normal and three with abnormal cytogenetics at diagnosis). In keeping with other smaller series, the presence of chromosomal abnormalities may have had a role in disease transformation in patients with PV; survival was not affected likely due to short follow-up.

DOI: 10.3109/10428194.2013.784970
0204060201520162017
Citations per Year

Citation Velocity: 8

Averaging 8 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.

Cite this paper

@article{Sever2013SignificanceOC, title={Significance of cytogenetic abnormalities in patients with polycythemia vera.}, author={Matjaz Sever and Alfonso Quint{\'a}s-Cardama and Sherry A. Pierce and Lingsha Zhou and Hagop M Kantarjian and Srdan Verstovsek}, journal={Leukemia & lymphoma}, year={2013}, volume={54 12}, pages={2667-70} }